Erasca, Inc. (ERAS)
Latest ERAS Insider Trades
- Ebun Garner - OfficerOpen-market sale$1.31M
Shannon Morris - OfficerOpen-market sale$301K- Ebun Garner - Officer
About Erasca, Inc. (ERAS)
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
- SAN DIEGO, CA
- 103
- 2021
- XNAS
90-Day SEC Filing Activity
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 7 | 1,479,328 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
ERAS Insider Transactions (Form 4)
2921 Form 4 filings on record, the earliest from Jun 24, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Charles S. Fuchs - Officer | Grant or award | Stock option (right to buy) | 1,300,000 |
Recent ERAS Form 8-K Filings
5Recent ERAS Form 144 Notices of Proposed Sale
3A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Erasca Foundation | Foundation | 8,333 | $152K | View on EDGAR | |
| - | - |
ERAS Insider Trading - FAQ
What is the latest insider trade for ERAS?
Erasca, Inc. (ERAS) had 7 insider filings in the last 90 days, with the most recent on 2026-08-12. The full record for ERAS runs to 21 Form 4 filings, the earliest from 2025-06-24. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying ERAS stock?
No insider purchases of ERAS were filed in the last 90 days.
How many insiders are selling ERAS stock?
No insider sales of ERAS were filed in the last 90 days. 3 sales are on record for this company.
Where can I see ERAS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page tracks ERAS Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow ERAS insider buys?
Create a free InsiderAlpha account and press Watch on this page to add ERAS to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
More Health Care Companies with Insider Activity
Recent Insider Filings
10Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
- - Charles S. Fuchs view on EDGAR
- - Valerie Denise Harding Start view on EDGAR
- - Jean I. Liu view on EDGAR
- - Pratik S. Multani view on EDGAR
- - Alexander W. Casdin view on EDGAR
- - Julie Hambleton view on EDGAR
- - James Arthur Bristol view on EDGAR
- - Ebun Garner view on EDGAR
- - Shannon Morris view on EDGAR
Related Companies - Recent Insider Activity
Learn More
- What is SEC Form 4?
- The filing insiders must submit within two business days of a trade, and how to read its transaction codes.
- Insider activity in Health Care
- Where ERAS's peers are being bought and sold.
- Every recent Form 4
- The full market-wide feed, updated as filings arrive from SEC EDGAR.
Track ERAS insider activity as it files
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
